ArticleCureus2026
Fibrosis-4 (FIB-4) Index Is Associated With Skeletal Muscle Mass in Japanese Patients With Type 2 Diabetes: A Single-Center Retrospective Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Liver fibrosis is increasingly recognized as a metabolic complication that may contribute to reduced skeletal muscle mass in type 2 diabetes. While the fibrosis-4 (FIB-4) index is a widely used non-invasive liver fibrosis marker, its clinical utility for assessing muscle mass remains unclear. Chronic inflammation and insulin resistance, which drive liver fibrosis, are also implicated in muscle degradation via the liver-muscle axis. We investigated the association between the FIB-4 index and low skeletal muscle mass index (SMI) in Japanese patients with type 2 diabetes, focusing on the influence of age. Methods This retrospective, cross-sectional study included 476 outpatients. SMI was assessed via bioelectrical impedance analysis; low SMI was defined by the Asian Working Group for Sarcopenia (AWGS) 2019 criteria. The relationship between the FIB-4 index and low SMI was evaluated using multiple logistic regression analyses and the Cochran-Mantel-Haenszel test, stratified by age (<65 vs. ≥65 years). Results Low SMI was identified in 111 (23%) of participants. In multivariable models adjusted for sex, BMI, and cerebrovascular disease, FIB-4 index was significantly associated with low SMI (OR 1.65, 95% CI 1.07-2.56, P=0.02). However, when age was added as a covariate, this association lost statistical significance (OR 0.83, 95% CI 0.48-1.42, P=0.50). Subgroup analysis revealed that in patients aged <65 years, those with FIB-4 index ≥1.3 had a significantly higher prevalence of low SMI (χ
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.